INTRODUCTION: In January 2017, mifepristone-induced medical abortion was made available in Canada. In this study, we will seek to (1) understand facilitators and barriers to the implementation of mifepristone across Canada, (2) assess the impact of a 'community of practice' clinical and health service support platform and (3) engage in and assess the impact of integrated knowledge translation (iKT) activities aimed to improve health policy, systems and service delivery issues to enhance patient access to mifepristone. METHODS AND ANALYSIS: This prospective mixed-methods implementation study will involve a national sample of physicians and pharmacists recruited via an online training programme, professional networks and a purpose-built commu...
BACKGROUND: Since 2016, abortion care has undergone several important changes, particularly related ...
OBJECTIVE: To explore the Canadian first-trimester medication abortion (MA) workforce and their clin...
We conducted a cross-sectional survey of abortion facilities from professional networks in the Unite...
Abstract Background Direct primary care provision of ...
BACKGROUND: Since Canadian drug regulatory approval of mifepristone for medical abortion in 2015 and...
PURPOSE: Access to family planning health services in Canada has been historically inadequate and in...
INTRODUCTION: Pharmacists were acknowledged as the most appropriate healthcare professional to dispe...
Background Since Canadian drug regulatory approval of mifepristone for medical abor...
Despite the decriminalization of abortion in Canada in 1988, women still face many barriers to abort...
Mifepristone medication abortion was first approved in China and France more than 30 years ago and i...
BACKGROUND: Virtual communities of practice (VCoPs) have been used to support innovation and quality...
Objectives: Mifepristone for first-trimester medical termination of pregnancy (MTOP) became availabl...
BACKGROUND: In the United States, mifepristone is available for medical abortion (for use with misop...
OBJECTIVES: Mifepristone was approved for use in medical abortion by Health Canada in 2015. Approval...
We conducted a cross-sectional survey of abortion facilities from professional networks in the Unite...
BACKGROUND: Since 2016, abortion care has undergone several important changes, particularly related ...
OBJECTIVE: To explore the Canadian first-trimester medication abortion (MA) workforce and their clin...
We conducted a cross-sectional survey of abortion facilities from professional networks in the Unite...
Abstract Background Direct primary care provision of ...
BACKGROUND: Since Canadian drug regulatory approval of mifepristone for medical abortion in 2015 and...
PURPOSE: Access to family planning health services in Canada has been historically inadequate and in...
INTRODUCTION: Pharmacists were acknowledged as the most appropriate healthcare professional to dispe...
Background Since Canadian drug regulatory approval of mifepristone for medical abor...
Despite the decriminalization of abortion in Canada in 1988, women still face many barriers to abort...
Mifepristone medication abortion was first approved in China and France more than 30 years ago and i...
BACKGROUND: Virtual communities of practice (VCoPs) have been used to support innovation and quality...
Objectives: Mifepristone for first-trimester medical termination of pregnancy (MTOP) became availabl...
BACKGROUND: In the United States, mifepristone is available for medical abortion (for use with misop...
OBJECTIVES: Mifepristone was approved for use in medical abortion by Health Canada in 2015. Approval...
We conducted a cross-sectional survey of abortion facilities from professional networks in the Unite...
BACKGROUND: Since 2016, abortion care has undergone several important changes, particularly related ...
OBJECTIVE: To explore the Canadian first-trimester medication abortion (MA) workforce and their clin...
We conducted a cross-sectional survey of abortion facilities from professional networks in the Unite...